Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Up 2.1% – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) rose 2.1% during trading on Wednesday . The stock traded as high as $16.52 and last traded at $14.1450. Approximately 219,729 shares traded hands during mid-day trading, an increase of 310% from the average daily volume of 53,599 shares. The stock had previously closed at $13.85.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. BTIG Research started coverage on Sensei Biotherapeutics in a research report on Thursday, June 11th. They set a “buy” rating and a $55.00 target price for the company. Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective for the company. Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Friday, April 24th. Finally, Loop Capital set a $50.00 target price on shares of Sensei Biotherapeutics in a research note on Thursday, May 28th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sensei Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $48.00.

Sensei Biotherapeutics Price Performance

The business has a 50 day moving average of $16.97 and a 200 day moving average of $19.65. The firm has a market capitalization of $18.98 million, a price-to-earnings ratio of -0.10 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83).

Insider Buying and Selling at Sensei Biotherapeutics

In related news, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the transaction, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This trade represents a 16.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently bought and sold shares of the company. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics during the first quarter worth $22,758,000. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. Bank of America Corp DE increased its position in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the period. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.